Michele T. Del Vecchio

Michele T. Del Vecchio

Milan, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 130 publications

COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in BRAF V600-Mutant Advanced Melanoma.

COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in BRAF V600-Mutant Advanced Melanoma.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: August 12, 2026

Adjuvant Approaches in Fully Resected Stage III and IV Cutaneous Melanoma: Where Are We Now?

Adjuvant Approaches in Fully Resected Stage III and IV Cutaneous Melanoma: Where Are We Now?

Journal: Cancers

Published: May 04, 2026

CAR-engineering of innate and innate-like immune cells: a new horizon in adoptive cell therapy for solid tumors.

CAR-engineering of innate and innate-like immune cells: a new horizon in adoptive cell therapy for solid tumors.

Journal: Journal for immunotherapy of cancer

Published: April 18, 2026

Adjuvant Therapy for High-Risk Stage II Cutaneous Melanoma: Insights and Future Directions.

Adjuvant Therapy for High-Risk Stage II Cutaneous Melanoma: Insights and Future Directions.

Journal: Cancers

Published: April 16, 2026

primary analysis of the RANDOMIZED eortc-2139/columbus-ad trial: Adjuvant encorafenib and binimetinib versus placebo in high-risk stage II BRAF-V600E/K melanoma.

primary analysis of the RANDOMIZED eortc-2139/columbus-ad trial: Adjuvant encorafenib and binimetinib versus placebo in high-risk stage II BRAF-V600E/K melanoma.

Journal: European journal of cancer (Oxford, England : 1990)

Published: April 16, 2026

Neoadjuvant Therapy and the Evolving Management of Resectable Advanced Melanoma.

Neoadjuvant Therapy and the Evolving Management of Resectable Advanced Melanoma.

Journal: Cancers

Published: April 14, 2026

New Perspectives and Open Issues in the Adjuvant and Neoadjuvant Treatment of Melanoma.

New Perspectives and Open Issues in the Adjuvant and Neoadjuvant Treatment of Melanoma.

Journal: Cancers

Published: April 14, 2026

Circulating thymidine kinase activity predicts survival and optimal treatment sequencing in BRAF-mutated metastatic melanoma in the SECOMBIT trial.

Circulating thymidine kinase activity predicts survival and optimal treatment sequencing in BRAF-mutated metastatic melanoma in the SECOMBIT trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: April 13, 2026

Discontinuation of combo immunotherapy and outcome of patients with melanoma brain metastases.

Discontinuation of combo immunotherapy and outcome of patients with melanoma brain metastases.

Journal: Journal for immunotherapy of cancer

Published: March 31, 2026

Mucosal Melanoma of the Head and Neck: A 45-Year Experience of a Tertiary Cancer Center.

Mucosal Melanoma of the Head and Neck: A 45-Year Experience of a Tertiary Cancer Center.

Journal: Cancers

Published: March 17, 2026

Shifting toward chronicity: The new reality of chronic treatments and health conditions among adolescent and young adult patients with cancer.

Shifting toward chronicity: The new reality of chronic treatments and health conditions among adolescent and young adult patients with cancer.

Journal: Cancer

Published: February 20, 2026

Case Report: Long-term response to multimodal treatment in metastatic uveal melanoma.

Case Report: Long-term response to multimodal treatment in metastatic uveal melanoma.

Journal: Frontiers in immunology

Published: November 18, 2025

Showing 1-12 of 130

Last Updated: 09/26/2026